{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:15:42Z","timestamp":1790172942776,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T00:00:00Z","timestamp":1488499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clinthera.2017.02.010","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T20:50:01Z","timestamp":1490907001000},"page":"787-803.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis"],"prefix":"10.1016","volume":"39","author":[{"given":"Floortje","family":"van Nooten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Treur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystallia","family":"Pantiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Stoker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mata","family":"Charokopou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.02.010_bib1","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.2337\/diacare.27.6.1458","article-title":"Diabetic somatic neuropathies","volume":"27","author":"Boulton","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.02.010_bib2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1526-4637.2007.00347.x","article-title":"Painful diabetic neuropathy: Epidemiology, natural history, early diagnosis, and treatment options","volume":"9","author":"Veves","year":"2008","journal-title":"Pain Med"},{"key":"10.1016\/j.clinthera.2017.02.010_bib3","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2337\/diacare.28.4.956","article-title":"American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association","volume":"28","author":"Boulton","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.02.010_bib4","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2337\/dc05-2228","article-title":"The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes","volume":"29","author":"Davies","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.02.010_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.diabres.2015.04.031","article-title":"Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: a review of the literature","volume":"109","author":"Alleman","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2017.02.010_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1464-5491.2006.02057.x","article-title":"The financial costs of healthcare treatment for people with type 1 or type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy","volume":"24","author":"Currie","year":"2007","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2017.02.010_bib7","first-page":"401","article-title":"Association of patient-rated severity with other outcomes in patients with painful diabetic peripheral neuropathy","volume":"4","author":"Taylor-Stokes","year":"2011","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.clinthera.2017.02.010_bib8","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","volume":"76","author":"Bril","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2017.02.010_bib9","unstructured":"National Institute for Health and Care Excellence (NICE). Neuropathic pain\u2014pharmacological management. NICE clinical guideline CG173, Full guideline, November 2013. http:\/\/www.nice.org.uk\/guidance\/cg173\/evidence."},{"key":"10.1016\/j.clinthera.2017.02.010_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2017.02.010_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2017.02.010_bib12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(08)70228-X","article-title":"NGX-4010 C116 Study Group. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study","volume":"7","author":"Backonja","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2017.02.010_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1526-4637.2010.01004.x","article-title":"NGX-4010 C117 Study Group. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia","volume":"12","author":"Irving","year":"2011","journal-title":"Pain Med"},{"key":"10.1016\/j.clinthera.2017.02.010_bib14","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1212\/01.wnl.0000314647.35825.9c","article-title":"Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2017.02.010_bib15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ejp.731","article-title":"Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain","volume":"20","author":"Haanp\u00e4\u00e4","year":"2016","journal-title":"Eur J Pain"},{"key":"10.1016\/j.clinthera.2017.02.010_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jpain.2016.09.008","article-title":"Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomised, double-blind, placebo-controlled study","volume":"18","author":"Simpson","year":"2017","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2017.02.010_bib17","doi-asserted-by":"crossref","unstructured":"Vinik AI, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment versus standard of care in painful diabetic peripheral neuropathy: a randomised, open\u2013label, 52-week study. 51st EASD Annual Meeting, Stockholm, Sweden, 14\u201318 September 2015 (abstract 1068). http:\/\/www.easdvirtualmeeting.org.","DOI":"10.1186\/s12883-016-0752-7"},{"key":"10.1016\/j.clinthera.2017.02.010_bib18","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). CHMP post-authorisation summary of positive opinion for Qutenza, July 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/000909\/WC500190411.pdf."},{"key":"10.1016\/j.clinthera.2017.02.010_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2017.02.010_bib20","series-title":"Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care","year":"2009"},{"key":"10.1016\/j.clinthera.2017.02.010_bib21","unstructured":"National Institute for Health and Care Excellence (NICE). Neuropathic pain\u2014pharmacological management. NICE clinical guideline CG173 Appendix D, 2013. http:\/\/www.nice.org.uk\/guidance\/cg173\/evidence."},{"key":"10.1016\/j.clinthera.2017.02.010_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008242.pub2","article-title":"Amitriptyline for neuropathic pain and fibromyalgia in adults","volume":"12","author":"Moore","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2017.02.010_bib23","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","volume":"3","author":"Moore","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2017.02.010_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007938","article-title":"Pregabalin for acute and chronic pain in adults","volume":"3","author":"Moore","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2017.02.010_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007115.pub2","article-title":"Duloxetine for treating painful neuropathy or chronic pain","volume":"4","author":"Lunn","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2017.02.010_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005454.pub2","article-title":"Antidepressants for neuropathic pain","volume":"4","author":"Saarto","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2017.02.010_bib27","unstructured":"National Institute for Health and Care Excellence. PMG9. Guide to the methods of technology appraisal 2013: NICE article, April 2013. http:\/\/www.nice.org.uk\/article\/pmg9\/chapter\/foreword."},{"key":"10.1016\/j.clinthera.2017.02.010_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2017.02.010_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pain.2010.07.031","article-title":"NeuPSIG guidelines on neuropathic pain assessment","volume":"152","author":"Haanp\u00e4\u00e4","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2017.02.010_bib31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/papr.12054","article-title":"Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy","volume":"14","author":"Snedecor","year":"2014","journal-title":"Pain Pract"},{"key":"10.1016\/j.clinthera.2017.02.010_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2017.02.010_bib33","unstructured":"Dias S, Sutton AJ, Ades AE, Welton NJ. NICE DSU Technical Support Document 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomised controlled trials. 2011 (April 2014 update). 1\u201398. http:\/\/www.nicedsu.org.uk."},{"key":"10.1016\/j.clinthera.2017.02.010_bib34","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","year":"2011"},{"key":"10.1016\/j.clinthera.2017.02.010_bib35","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2337\/dc12-0656","article-title":"Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: Impact on pain, polysomnographic sleep, daytime functioning, and quality of life","volume":"35","author":"Boyle","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.02.010_bib36","first-page":"745","article-title":"Amitriptyline vs pregabalin in painful diabetic neuropathy: a randomised placebo-based study","volume":"5","author":"Shabbir","year":"2011","journal-title":"Pakistan J Med Heal Sci"},{"key":"10.1016\/j.clinthera.2017.02.010_bib37","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.37.4.589","article-title":"Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood","volume":"37","author":"Max","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2017.02.010_bib38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0885-3924(00)00181-0","article-title":"Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study","volume":"20","author":"Dallocchio","year":"2000","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2017.02.010_bib39","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","article-title":"A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain","volume":"67","author":"Wernicke","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2017.02.010_bib40","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.2040-1124.2010.00073.x","article-title":"Superiority of duloxetine to placebo in improving diabetic neuropathic pain: results of a randomized controlled trial in Japan","volume":"2","author":"Yasuda","year":"2011","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinthera.2017.02.010_bib41","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","article-title":"Duloxetine and pregabalin: high-dose monotherapy or their combination? The \u201cCOMBO-DN study\u201d\u2014a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain","volume":"154","author":"Tesfaye","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2017.02.010_bib42","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/papr.12080","article-title":"Efficacy and safety of carisbamate in patients with diabetic neuropathy or postherpetic neuralgia: Results from 3 randomized, double-blind placebo-controlled trials","volume":"14","author":"Smith","year":"2014","journal-title":"Pain Pract"},{"key":"10.1016\/j.clinthera.2017.02.010_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1464-5491.2010.03152.x","article-title":"Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial","volume":"28","author":"Satoh","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2017.02.010_bib44","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1526-4637.2005.00061.x","article-title":"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain","volume":"6","author":"Raskin","year":"2005","journal-title":"Pain Med"},{"key":"10.1016\/j.clinthera.2017.02.010_bib45","first-page":"3184","article-title":"Duloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in China","volume":"123","author":"Gao","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.clinthera.2017.02.010_bib46","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/papr.12014","article-title":"A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy","volume":"13","author":"Rauck","year":"2013","journal-title":"Pain Pract"},{"key":"10.1016\/j.clinthera.2017.02.010_bib47","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1212\/01.WNL.0000145767.36287.A1","article-title":"Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial","volume":"63","author":"Lesser","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2017.02.010_bib48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2377-8-33","article-title":"Efficacy and safety of pregabalin 600 mg\/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial","volume":"8","author":"Arezzo","year":"2008","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinthera.2017.02.010_bib49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpain.2007.05.003","article-title":"Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: A randomized, double-blind study","volume":"12","author":"T\u00f6lle","year":"2008","journal-title":"Eur J Pain"},{"key":"10.1016\/j.clinthera.2017.02.010_bib50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pain.2005.03.029","article-title":"Duloxetine vs. placebo in patients with painful diabetic neuropathy","volume":"116","author":"Goldstein","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2017.02.010_bib51","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.diabres.2012.03.010","article-title":"A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial","volume":"97","author":"Sandercock","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2017.02.010_bib52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","article-title":"Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial","volume":"6","author":"Richter","year":"2005","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2017.02.010_bib53","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","article-title":"Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial","volume":"110","author":"Rosenstock","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2017.02.010_bib54","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","article-title":"Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial","volume":"280","author":"Backonja","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2017.02.010_bib55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00131402-200112000-00002","article-title":"Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy","volume":"3","author":"Simpson","year":"2001","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.clinthera.2017.02.010_bib56","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/jnnp.66.2.251","article-title":"Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial","volume":"66","author":"Gorson","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2017.02.010_bib57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/0253-7613.91867","article-title":"Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy","volume":"44","author":"Devi","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.clinthera.2017.02.010_bib58","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/JCP.0b013e31820f4f57","article-title":"Effects of pregabalin on heart rate variability in patients with painful diabetic neuropathy","volume":"31","author":"Jiang","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2017.02.010_bib59","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report. Qutenza, international non-proprietary name: capsaicin. Procedure No. EMEA\/H\/C\/000909\/II\/0039. EMA\/545605\/2015, 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000909\/WC500195227.pdf."},{"key":"10.1016\/j.clinthera.2017.02.010_bib60","first-page":"E705","article-title":"Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: A network meta-analysis","volume":"16","author":"Rudroju","year":"2013","journal-title":"Pain Physician"},{"key":"10.1016\/j.clinthera.2017.02.010_bib61","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2377-9-6","article-title":"Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain","volume":"9","author":"Quilici","year":"2009","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinthera.2017.02.010_bib62","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7326\/M14-0511","article-title":"Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis","volume":"161","author":"Griebeler","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2017.02.010_bib63","first-page":"389","article-title":"Pregabalin as a treatment for painful diabetic peripheral neuropathy: A meta-analysis","volume":"33","author":"Hurley","year":"2008","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.clinthera.2017.02.010_bib64","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/aas.12420","article-title":"Efficacy and safety of pregabalin for treating painful diabetic peripheral neuropathy: A meta-analysis","volume":"59","author":"Zhang","year":"2015","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.clinthera.2017.02.010_bib65","first-page":"297","article-title":"5% Lidocaine medicated qplaster in painful diabetic peripheral neuropathy (DPN): A systematic review","volume":"140","author":"Wolff","year":"2010","journal-title":"Swiss Med Wkly"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817301315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817301315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T07:55:23Z","timestamp":1568966123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817301315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0149291817301315"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.02.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}